These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30136084)

  • 1. Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy.
    Allen M; Wang X; Serie DJ; Strickland SL; Burgess JD; Koga S; Younkin CS; Nguyen TT; Malphrus KG; Lincoln SJ; Alamprese M; Zhu K; Chang R; Carrasquillo MM; Kouri N; Murray ME; Reddy JS; Funk C; Price ND; Golde TE; Younkin SG; Asmann YW; Crook JE; Dickson DW; Ertekin-Taner N
    Acta Neuropathol; 2018 Nov; 136(5):709-727. PubMed ID: 30136084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration.
    Briel N; Pratsch K; Roeber S; Arzberger T; Herms J
    Brain Pathol; 2021 Jul; 31(4):e12914. PubMed ID: 33089580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
    Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
    Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures.
    Valentino RR; Tamvaka N; Heckman MG; Johnson PW; Soto-Beasley AI; Walton RL; Koga S; Uitti RJ; Wszolek ZK; Dickson DW; Ross OA
    Acta Neuropathol Commun; 2020 Sep; 8(1):162. PubMed ID: 32943110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death.
    Zhang L; Toyoshima Y; Takeshima A; Shimizu H; Tomita I; Onodera O; Takahashi H; Kakita A
    Neuropathology; 2021 Jun; 41(3):174-182. PubMed ID: 33205528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial patterns of the tau pathology in progressive supranuclear palsy.
    Armstrong RA; Cairns NJ
    Neurol Sci; 2013 Mar; 34(3):337-44. PubMed ID: 22411688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.
    Allen M; Burgess JD; Ballard T; Serie D; Wang X; Younkin CS; Sun Z; Kouri N; Baheti S; Wang C; Carrasquillo MM; Nguyen T; Lincoln S; Malphrus K; Murray M; Golde TE; Price ND; Younkin SG; Schellenberg GD; Asmann Y; Ordog T; Crook J; Dickson D; Ertekin-Taner N
    Acta Neuropathol; 2016 Aug; 132(2):197-211. PubMed ID: 27115769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process.
    Togo T; Dickson DW
    Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.
    Roemer SF; Grinberg LT; Crary JF; Seeley WW; McKee AC; Kovacs GG; Beach TG; Duyckaerts C; Ferrer IA; Gelpi E; Lee EB; Revesz T; White CL; Yoshida M; Pereira FL; Whitney K; Ghayal NB; Dickson DW
    Acta Neuropathol; 2022 Oct; 144(4):603-614. PubMed ID: 35947184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between histopathological features of progressive supranuclear palsy and disease duration.
    Josephs KA; Mandrekar JN; Dickson DW
    Parkinsonism Relat Disord; 2006 Mar; 12(2):109-12. PubMed ID: 16337422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy.
    Valentino RR; Koga S; Heckman MG; Brushaber DE; Diehl NN; Walton RL; Dickson DW; Ross OA
    Mov Disord; 2020 May; 35(5):890-894. PubMed ID: 32142177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
    Ferrer I; Barrachina M; Puig B
    Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW
    Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.
    Ferrer I; Blanco R; Carmona M; Puig B
    J Neural Transm (Vienna); 2001; 108(12):1397-415. PubMed ID: 11810404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases.
    Armstrong RA; Lantos PL; Cairns NJ
    J Neural Transm (Vienna); 2007; 114(12):1569-77. PubMed ID: 17680229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease.
    Borroni B; Agosti C; Magnani E; Di Luca M; Padovani A
    Curr Med Chem; 2011; 18(17):2655-60. PubMed ID: 21568901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional quantitative analysis of tau-positive neurons in progressive supranuclear palsy: comparison with Alzheimer's disease.
    Li F; Iseki E; Odawara T; Kosaka K; Yagishita S; Amano N
    J Neurol Sci; 1998 Jul; 159(1):73-81. PubMed ID: 9700707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
    Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
    JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).
    Dickson DW; Kouri N; Murray ME; Josephs KA
    J Mol Neurosci; 2011 Nov; 45(3):384-9. PubMed ID: 21720721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy.
    Takahashi M; Weidenheim KM; Dickson DW; Ksiezak-Reding H
    J Neuropathol Exp Neurol; 2002 Jan; 61(1):33-45. PubMed ID: 11829342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.